Diagnostics Saves Roche From Q1 Difficulties
Executive Summary
In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues.
You may also be interested in...
FDA Authorizes At-Home COVID-19/Influenza Testing Kits As World Braces For Tough Flu Season
Labcorp’s combined COVID-19 and influenza A/B test has received emergency use approval in a bid to minimize spread of both illnesses during this winter.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
Stock Watch: J&J And Roche Invite Comparison
Recovering pharmaceutical and medical device revenues at J&J hint at the green shoots germinating from the pandemic. Roche’s COVID-19 diagnostics revenue growth was its own green shoot, but can these be maintained as the pandemic evolves?